Full-Time

Research Technician

Analytics & Mass Spectrometry

Posted on 9/18/2023

AbCellera Biologics

AbCellera Biologics

501-1,000 employees

Biotechnology firm specializing in antibody therapies

No salary listed

Junior, Mid

Vancouver, BC, Canada

Category
Lab & Research
Required Skills
Communications
Management
Data Analysis
Requirements
  • Conduct characterization of antibodies and other proteins using analytical techniques, with a focus on mass spectrometry (MS), liquid chromatography (UHPLC), and capillary electrophoresis (CE)
  • Perform routine antibody analyses to support the progression of therapeutic programs; including sample preparation using lab automation tools
  • Contribute to assay development, troubleshooting and instrument maintenance
  • Collaborate with teammates to solve problems, analyze, interpret data and communicate results to a multidisciplinary team
  • Work together with laboratory management; including keeping inventory of consumables and reagents
  • Grow your technical skill set and engage in professional development
  • You are excited about proteins, the characterization of proteins, and are eager to learn new lab techniques!
  • You are a creative problem solver and fast learner who believes in team work to tackle the most challenging scientific problems
  • You are self-motivated and have the initiative and drive to meet goals under tight project timelines
  • You have excellent documentation, organizational and communication skills
  • You have impeccable attention to detail
  • MSc or BSc with an additional 2+ years of experience in Analytical Chemistry, Chemistry, Biochemistry, Biotechnology and Health Science, or relevant science degree
  • Hands-on experience with mass spectrometry techniques such as intact mass analysis or peptide mapping using high resolution MS systems
  • Hands-on experience using analytical or biophysical techniques. Experience with one or more of analytical chromatography (HPLC / UPLC), Spectroscopy, or capillary electrophoresis (CE-SDS) for protein characterization is preferred
  • Experience working with larger numbers of protein samples, high throughput assays and a desire to work with automated liquid handling systems is preferred
  • Experience with laboratory information management systems (LIMS) will be a strong asset but not required
  • Excellent communication and problem solving skills
  • Strong time management, organizational skills and attention to detail
  • Strong data analysis skills and the ability to interpret, communicate, and document large data sets

AbCellera specializes in discovering and developing therapeutic antibodies for various diseases. The company uses a proprietary technology platform that combines different scientific methods to identify and create antibodies efficiently. Clients, including pharmaceutical companies and research institutions, partner with AbCellera to enhance their drug development processes. Unlike many competitors, AbCellera focuses on challenging targets that traditional methods struggle to address. The company's goal is to accelerate the development of new antibody therapies through collaborations, licensing agreements, and advancing its own therapeutic programs.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Vancouver, Canada

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • AbCellera's collaboration with Biogen targets the challenging blood-brain barrier in neuroscience.
  • Partnerships with Viking and ArrowMark aim to launch new biotech companies in immunology.
  • The growing trend of AI-driven discovery complements AbCellera's existing technology strengths.

What critics are saying

  • Increased competition from AI-integrated drug discovery firms may challenge AbCellera's market position.
  • Dependency on major partners like AbbVie and Eli Lilly could pose risks if relationships change.
  • Scientific challenges in crossing the blood-brain barrier may delay Biogen collaboration outcomes.

What makes AbCellera Biologics unique

  • AbCellera excels in rapid antibody discovery with its integrated technology platform.
  • The company has strong partnerships with leading pharmaceutical firms like AbbVie and Eli Lilly.
  • AbCellera's focus on T-cell engagers positions it at the forefront of oncology innovation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Paid Sick Leave

Flexible Work Hours

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Montreal Gazette
Mar 25th, 2025
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera announces presentation of in vivo data on PSMA x CD3 T-Cell engagers at AACR 2025.

Stock Titan
Jan 13th, 2025
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera (ABCL) has expanded its collaboration with AbbVie (ABBV) to develop novel T-cell engagers (TCE) in oncology, building upon their partnership from December 2022.

North Carolina Biotechnology Center
Sep 30th, 2024
Dualogics Sells Antibody Platform to Canadian Company | North Carolina Biotechnology Center

Durham-based Dualogics has sold its core technology for producing therapeutic antibodies to a Canadian biotechnology company.

Stock Titan
Jul 31st, 2024
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

AbCellera (Nasdaq: ABCL) has expanded its collaboration with Eli Lilly to develop antibody medicines for immunology, cardiovascular disease, and neuroscience programs.

Securities.io
Jun 13th, 2024
Top 10 Biotech Big Data Companies

More Data For Better MedicineThe more we learn about biology, the more we realize all we do not know. It started with the genomic revolution and the first human genome sequenced in the early 2000s.Genomics has now been joined by other datasets like transcriptomics, proteomics, metabolomics, microbiome, etc. forming a new “multiomics” science. We discussed in further detail this evolution in “ Multiomics Are The Next Step In Biotechnology ”.These new tools have created a flood of data bringing detailed information about the inner activities of cells sometimes down to the atomic level. A key driver of this data growth has been the collapse of price of sequencing gene and other biological materials like proteins.This has created enthusiasm about “Big Data” potential in biotech, mimicking the concept of big data from other, more IT-driven fields.Already in 2018, the magazine Barron’s was asking “ Will Big Data Lead to Big Biotech Returns? ” and the industry started to ask “ Implementing Large-Scale Data Processing and Analysis for Bioprocessing ”Quite a few companies are well-positioned to benefit from the drive to create and analyze at-scale biological data.AI Merging With Big Data?A new development in the last few years has been the emergence of AI. While AI made its way into public consciousness mostly in 2023, with LLMs (Large Language Models) like ChatGPT, the biotech industry started to embrace AI many years before that.And it makes sense because data and AI have a somewhat symbiotic relationship:Training AI models requires a lot of data with high quality and annotations.AIs can help sort out massive datasets without direct human intervention and connect the dots where manual analysis would not be possible.The result is that today, a lot of the previously big data-focused companies in the biotech industry are also turning into AI companies.Contrary to some AI applications still looking for a business model (like image generation), drug discovery and medical research have a pretty straightforward path from AI model to monetization.Top 10 Big Data Biotech StocksIllumina is the leading genomics company, by far the largest and most established in the industry, with $1.2B in revenues, which grew 11% CAGR in the last 5 years.This also makes it the prime provider of genomic data to the entirety of the biotech industry.Like most genome sequencing companies, Illumina makes money when selling sequencers but mostly when selling the consumables used by the sequencers

INACTIVE